Studies have demonstrated that low IGFBP-3 and high IGF-1 and IGFBP-2 levels are associated with high cancer risk, poor prognosis, and tumor metastasis in several cancers, including CRC, breast cancer, and prostate cancer; however, these findings remain controversial and can be population specific [7,8,9]. This evidence concerns the gene IGF1 and colorectal carcinoma.